title: Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
abstract: OBJECTIVE
  Overactive bladder (OAB) is common in men and may exist concomitantly with benign prostatic hyperplasia (BPH) and obstruction. We present a subanalysis of results from men with OAB in a 6-month, open-label study of treatment with the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorporated to yield a clinically representative population.
  
  
  METHODS
  All participants received OXY-TDS 3.9 mg/day. Effectiveness was assessed by changes in scores on validated questionnaires, which included the single-item Patient Perception of Bladder Condition (PPBC), the King's Health Questionnaire (KHQ) and the Beck Depression Inventory-II (BDI-II).
  
  
  RESULTS
  The proportion of men (n=369; mean age=69.6 years) who reported that their bladder condition caused moderate, severe or many severe problems (PPBC>or=4) improved from 77.3% at baseline to 38.1-53.6% in subsequent months. Mean KHQ scores decreased significantly (p<or=0.0196) from baseline to study end in eight of 10 domains, indicating improved health-related quality of life. The proportion of men with BDI-II score>12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9% (p=0.0055). Men with a history of 'prostate problems' or use of 'BPH medication' (32.2%) had KHQ domain changes that were similar (p>or=0.1016) to those of other men. Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.
  
  
  CONCLUSIONS
  Oxybutynin transdermal system treatment of men with OAB was effective and well tolerated, regardless of history of prostate condition.
authors.affiliation: Weill Medical College of Cornell University, New York, NY 10021, USA. das2021@med.cornell.edu
authors.forename: D R
authors.initials: DR
authors.lastname: Staskin
authors.forename: M T
authors.initials: MT
authors.lastname: Rosenberg
authors.forename: N V
authors.initials: NV
authors.lastname: Dahl
authors.forename: P V
authors.initials: PV
authors.lastname: Polishuk
authors.forename: N R
authors.initials: NR
authors.lastname: Zinner
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications*; D011788:Quality of Life; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin